Prostate Cancer
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T Cell-redirecting agent targeting Human Kallikrein 2, with Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer (78278343PCR3003 (KLK2-PASenger))
- Details
ClinicalTrials.gov ID:
NCT07225946
Diagnosis Type:
NA
USOR Number:
- Address
,
P: